#pandemic

A Game Changer in COVID-19 Prevention: Shionogi's Ensitrelvir Reduces Risk by 67% Post-Exposure

A landmark study published today reveals Shionogi's oral antiviral, Ensitrelvir, can significantly cut COVID-19 risk after exposure. This breakthrough, showing a 67% reduction in symptomatic infection, marks a pivotal moment in our ongoing fight against the virus, offering a crucial new layer of protection.